Reuters Insider - Pfizer's, Merck's revenue disappoint investors

Procter & Gamble Health

01/05/2018 16:54

Click the following link to watch video: https://share.insider.thomsonreuters.com/link?entryId=0_x0l8xila&referenceId=tag:reuters.com,2018:newsml_OV8E1FS0B_930&pageId=ReutersNews
Source: Reuters Insider

Description: Sales of Pfizer's blockbuster drug Ibrance zoomed higher but
missed forecasts. Sales of Merck's cancer drug Keytruda catapulted higher, but
overall revenue disappointed Wall Street. Fred Katayama reports.
Short Link: https://reut.rs/2Fuuovf